首页/数据集/NK cell-triggered CCL5/IFNg-CXCL9/10 axis underlies the clinical efficacy of HER2-targeted antibodies in primary HER2-positive breast cancer

NK cell-triggered CCL5/IFNg-CXCL9/10 axis underlies the clinical efficacy of HER2-targeted antibodies in primary HER2-positive breast cancer

NIAID Data Ecosystem2026-05-01 收录

HER2阳性乳腺癌

肿瘤临床疗效机制

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230540 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2024-01-11

相关数据集

Majordata_HER2_Based_20250416_临床数据集

HER2阳性乳腺癌

临床预后分析

本数据集为HER2阳性乳腺癌患者的匿名纵向临床数据，包含人口统计学信息、活检数据、病理报告、实验室结果、HER2评分、治疗参数及长期随访数据，用于HER2检测标准化和预后分析，通过维也纳医科大学伦理审查。 Zenodo平台（文件命名：Majordata_HER2_20250416_Zenodo）

海数据50

Table_1_Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel.DOCX

HER2阳性乳腺癌

癌症生存预测模型

Background: HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients consider

NIAID Data Ecosystem40

Supplementary Table 1. Economic burden of central nervous system metastases in human epidermal growth factor receptor 2–positive breast cancer

肿瘤医疗经济学

HER2阳性乳腺癌

Supplementary Table 1. Primary diagnoses of interest.

Figshare2021-05-28 更新10

Determinants of survival in HER2+ metastatic esophagogastric cancer.

HER2阳性乳腺癌

精准医疗基因组学

This cohort contains serial WES alterations from patient samples collected as part of NCT02954536, a phase 2 evaluation of chemotherapy with trastuzumab and pembrolizumab in advanced/unresectable or m

NIAID Data Ecosystem40

RNA-seq of MMTV-Neu AXL KO tumors

HER2阳性乳腺癌

AXL受体酪氨酸激酶

AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. We report that AXL is also detected in HER2+ breast cancer specimens where its expression correlates with p

NIAID Data Ecosystem30